Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: A double-blind randomized controlled trial

Abstract

No direct comparison of tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) has yet been carried out in the treatment of liver cirrhosis in China. We designed a double-blind randomized trial to evaluate the potential therapeutic efficacy of TUDCA in liver cirrhosis, using UDCA as parallel control. The enrolled 23 patients with liver cirrhosis were randomly divided into TUDCA group (n=12) and UDCA group (n=11), and given TUDCA and UDCA respectively at the daily dose of 750 mg, in a randomly assigned sequence for a 6-month period. Clinical, biochemical and histological features, and liver ultrasonographic findings were evaluated before and after the study. According to the inclusion criteria, 18 patients were included in the final analysis, including 9 cases in both two groups. Serum ALT, AST and ALP levels in TUDCA group and AST levels in UDCA group were significantly reduced as compared with baseline (P<0.05). Serum albumin levels were significantly increased in both TUDCA and UDCA groups (P<0.05). Serum markers for liver fibrosis were slightly decreased with the difference being not significant in either group. Only one patient in TUDCA group had significantly histological relief. Both treatments were well tolerated and no patient complained of side effects. It is suggested that TUDCA therapy is safe and appears to be more effective than UDCA in the treatment of liver cirrhosis, particularly in the improvement of the biochemical expression. However, both drugs exert no effect on the serum markers for liver fibrosis during 6-month treatment.

Keywords

liver cirrhosis / tauroursodeoxycholic acid / ursodeoxycholic acid / serum markers

References

[1] KuiperEM, HansenBE, LesterhuisW, et al.. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol, 2011, 35(1): 29-33

[2] WangX, ShenS, LiN, et al.. Effect of ursodeoxycholi acid on liver cirrhosis with hepatitis B. Zhong Nan Da Xue Xue Bao Yi Xue Ban (Chinese), 2010, 35(2): 171-175

[3] FischerS, MullerI, ZundtBZ, et al.. Ursodeoxycholic acid decreases viscosity and sedimentable fractions of gallbladder bile in patients with cholesterol gallstones. Eur J Gastroenterol Hepatol, 2004, 16(3): 305-311

[4] RodriquesCM, KrenBT, SteerCJ, et al.. Tauroursodeoxycholate increases rat liver ursodeoxycholate levels and limits lithocholate formation better than ursodeoxycholate. Gastroenterology, 1995, 109(2): 564-572

[5] FickertP, FuchsbichlerA, MarschallHU, et al.. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am J Pathol, 2006, 168(2): 410-422

[6] InvernizziP, SetchellKDR, CrosignaniA, et al.. Differences in the metabolism and disposition of ursodeoxycholic acid and its taurine-conjugated species in patients with primary biliary cirrhosis. Hepatology, 1999, 29(2): 320-327

[7] CrosignaniA, BattezzatiPM, SetchellKD, et al.. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci, 1996, 41(4): 809-815

[8] SetchellKD, RodriguesCM, PoddaM, et al.. Metabolism of orally administered tauroursodeoxycholic acid in patients with primary biliary cirrhosis. Gut, 1996, 38(3): 439-446

[9] BoatrightJH, NickersonJM, MoringAG, et al.. Bile acids in treatment of ocular disease. J Ocul Biol Dis Infor, 2009, 2(3): 149-159

[10] Chinese Society of Infectious DiseasesParasitoloyChinese Society of Hepatology of Chinese Medical Association.. The programme of prevention and cure for viral hepatitis. Zhonggua Gan Zang Bing Za Zhi (Chinese), 2000, 8(6): 324-329

[11] WangTL, LiuX, ZhouYP. Inflammatory activity of chronic hepatitis and fibrosis scoring program. Zhong Hua Gan Zang Bing Za Zhi (Chinese), 1998, 6(4): 195-197

[12] CaglierisS, GianniniE, DardanoG, et al.. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists. Hepatogastroenterology, 2000, 47(34): 1045-1047

[13] ÚrizM, SáezE, PrietoJ, et al.. Ursodeoxycholic acid is conjugated with taurine to promote secretin-stimulated biliary hydrocholeresis in the normal rat. PLos One, 2011, 6(12): e28717

[14] Ben MosbahI, Alfany-FernandezI, MartelC, et al.. Endoplasmic reticulum stress inhibition protects steatotic and non-steatotic livers in partial hepatectomy under ischemia-reperfusion. Cell Death Dis, 2010, 8(1): e52

[15] RodriguesCM, SolaS, SharpeJC, et al.. Tauroursodeoxycholic acid prevents Bax-induced membrane perturbation and cytochrome C release in isolated mitochondria. Biochemistry, 2003, 42(10): 3070-3080

[16] SchoemakerMH, Conde de la RosaL, Buist-HomanM, et al.. Tauroursodeoxycholic acid protects rat hepatocytes from bile acid-induced apoptosis via activation of survival pathways. Hepatology, 2004, 39(6): 1563-1573

[17] TerasakiS, NakanumaY, OqinoH, et al.. Hepatocellular and biliary expression of HLA antigens in primary biliary cirrhosis before and after ursodeoxycholic acid therapy. Am J Gastroenterol, 1991, 86(9): 1194-1199

[18] LiuL, SakaquchiT, CuiX, et al.. Liver regeneration enhanced by orally administered ursodesoxycholic acid is mediated by immunosuppression in partially hepatectomized rats. Am J Clin Med, 2002, 30(1): 119-126

[19] KuiperEM, HansenBE, LesterhuisW, et al.. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol, 2011, 35(1): 29-33

[20] DanW, LingY, JinmingH, et al.. Tauroursodeoxycholic acid inhibits carbon tetrachloride-induced liver fibrosis in rats. Shi Jie Hua Ren Xiao Hua Za Zhi (Chinese), 2010, 18(19): 1979-1984

[21] ColellA, CollO, Garcia-RuizC, et al.. Tauroursodeoxycholic acid protects hepatocytes from ethanol-fed rats against tumor necrosis factor-induced cell death by replenishing mitochondrial glutathione. Hepatology, 2001, 34(5): 964-971

[22] ZhangLX, LiangTJ, TanYR, et al.. Protective effects of ursodeoxycholic acid against immune-mediated liver fibrosis in rats. Hepatogastroenterology, 2010, 57(102–103): 1196-1202

[23] VoumvourakiA, KoulentakiM, NotasG, et al.. Serum surrogate markers of liver fibrosis in primary biliary cirrhosis. Eur J Intern Med, 2011, 22(1): 77-83

[24] LarghiA, CrosignaniA, BattezzatiPM, et al.. Ursodeoxycholic and tauroursodeoxycholic acids for the treatment of primary biliary cirrhosis: a pilot crossover study. Aliment Pharmacol Ther, 1997, 11(2): 409-414